• Explore /
  • Poster
  • / SWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC).

SWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC).

Abstract Poster

Authors

Benjamin Maughan

Benjamin L. Maughan

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Benjamin L. Maughan , Melissa Plets , Sumanta Kumar Pal , Yasser Ged , Catherine Tangen , Ulka N. Vaishampayan , Seth P. Lerner , Ian M. Thompson Jr.

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05411081

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS493)

DOI

10.1200/JCO.2024.42.4_suppl.TPS493

Abstract #

TPS493

Poster Bd #

M14

Abstract Disclosures

Similar Posters

First Author: Deepak Kilari

First Author: Deepak Kilari

First Author: Katy Beckermann

First Author: Hung-Yang Kuo